Furthermore, ibrutinib-resistant TMD8 cells (ABC DLBCL) had elevated BCL2 expression and were vulnerable to BCL2 inhibition; samples from ABC DLBCL patients who had poorer responses to ibrutinib also exhibited higher BCL2 expression (130). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.